low-molecular weight heparin

low-molecular weight heparin

Enoxaparin/Lovenox®, dalteparin, fraxiparin Pharmacology A heparin with advantages over unfractionated heparin, which blocks thrombosis earlier in the coagulation cascade than conventional heparin by inhibiting factor Xa; it less likely to cause thrombocytopenia or thrombotic thrombocytopenia syndrome Indications DVT. See Deep vein thrombosis.
References in periodicals archive ?
Dec 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today the results of a study that demonstrated total hospital direct medical costs associated with VTE treatment are reduced by $550 per patient when they were treated with the use of low-molecular weight heparin (LMWH) vs.
In patients with confirmed VTE, evidence- based guidelines recommend treatment for a minimum of five days with either a low-molecular weight heparin (LMWH, such as Lovenox) or UFH.
In their study, the researchers administered a fixed dose of plain heparin by syringe to half of the 708 volunteers and a low-molecular weight heparin, also by syringe, to the others.
Taking low-molecular weight heparin preparation with a 87.
Yet, Chinese market of heparin drugs, in particular the market of low-molecular weight heparin, is dominated by foreign brands on account of technology barriers although China is the worlds key supplier of heparin sodium API.
Lovenox(R) is a Low-Molecular Weight Heparin, approved in the United States with the broadest range of indications -
Using Premier's Perspective(TM) database, researchers from Premier compared actual inpatient treatments to evidence-based prophylaxis guidelines involving the use of unfractionated (UH) and low-molecular weight heparin (LMWH) and compression devices put forth by the American College of Chest Physicians for several categories of medical and surgical diagnoses.
The study, "Cost Implications of Using Unfractionated Heparin or Enoxaparin in Medical Patients At-Risk for Venous Thromboembolic Events," reveals that patients treated with enoxaparin (a low-molecular weight heparin [LMWH]) had an average savings in cost per discharge of $1,002 compared to patients treated with UFH, despite higher drug acquisition costs for enoxaparin.
The ENOX test is used to detect the anticoagulant effects of Aventis Pharmaceuticals' enoxaparin sodium (Lovenox(R)), the number-one selling low-molecular weight heparin (LMWH) in the world, in unstable angina patients.
It is commonly used following initial treatment of venous thromboembolism with either unfractionated heparin or low-molecular weight heparin.
The final payment represents the conclusion of a $5 million two year test development program as PharmaNetics and Aventis now initiate a collaborative marketing and promotion program to promote the use of the ENOX test to detect the anticoagulant effects of Aventis Pharmaceuticals' enoxaparin sodium (Lovenox(R)), the number-one selling low-molecular weight heparin (LMWH) in the world.
The first eight chapters describe the pharmacology and clinical utility of common antiplatelet, antithrombin, and fibrinolytic agents, including aspirin, the thieneopyridines, glycoprotein IIb/IIIa inhibitors, unfractionated heparin, the low-molecular weight heparins, and direct thrombin inhibitors.

Full browser ?